Michael Landsittel

Mike, Chief Financial Officer of Blueprint Medicines, has over 15 years of experience as a senior finance professional with a strategic and operational focus. He previously served as Vice President, Finance of Blueprint Medicines from February 2016 to January 2019, and as Senior Director, Finance from September 2014 to February 2016.

Prior to joining Blueprint Medicines, Mike served as senior director of finance at Algeta US, where he led the US organization’s finance and operations efforts, which ultimately supported the successful launch of the prostate cancer drug XOFIGO┬« (radium Ra 223 dichloride). Before joining Algeta, Mike was the director of financial planning at Infinity Pharmaceuticals where he was responsible for budgeting and forecasting, including support of Infinity Pharmaceuticals’ long-range planning and capital markets activities. Prior to Infinity Pharmaceuticals, Mike held multiple business development and strategic planning roles for nearly 10 years at Genzyme. Mike is a registered CPA in the state of Illinois. He holds a B.B.A from the University of Michigan and an M.B.A. from the Tuck School of Business at Dartmouth College.